In brief
- CTech reported in May that MSICS claimed GMP licensing; this review did not inspect the ministry licence or an inventory proving exclusivity.
- The company has closed a $3.6 million funding round to scale production and accelerate trials for its MSX-06 candidate.
- In May, CTech described a multicenter PTSD project targeting 100 participants across four hospitals, awaiting authorization then; current status is not confirmed here.
According to CTech on 3 May 2026, Israeli startup MSICS Pharma had announced a $3.6 million funding round, with Fusion VC and GlenRock among its investors, to expand its psilocybin production capacity and advance its clinical program. CTech attributes GMP psilocybin-manufacturing licensing to the company. The ministry document, scope, validity and exclusivity were not checked. A GMP reference does not certify every batch or itself authorize sales or therapeutic access.
Who is behind it and where they stand
MSICS Pharma was founded by brothers Roei Zerahia, CEO, and Omer Zerahia, chief business officer, who previously led Canndoc, a medical cannabis company described by CTech in May as Nasdaq-listed. With a team of about twelve, the company is developing MSX-06, its medical psilocybin candidate, and in the May report claimed to be in phase 2 trials in Israel for treatment-resistant depression and obsessive-compulsive disorder. CTech quotes the company claiming remission of up to 70%. No denominator, duration, comparator or primary publication was verified here; the claim cannot be treated as an independent efficacy estimate or proof that the same trial remains ongoing today.
May’s announced plans: four hospitals and 100 patients
With the new capital, MSICS aims to accelerate a multicenter trial focused on post-traumatic stress disorder, designed to include 100 patients in collaboration with four Israeli hospitals. In the May report, the company said it was awaiting authorizations. Its website inspected on 20 October advertises recruitment for selected indications, but registries, permissions and places at each centre were not verified; this is not an independent clinical-status update. Looking ahead, the firm has signaled its intention to explore indications such as eating disorders. Part of the funding will also be used to expand the facility and prepare for potential supply to other markets.
What this implies
The report combines funding, industrial plans and clinical statements from an interested company. Licences, batches and a primary clinical outcome were not verified. Supply information should be distinguished from treatment permissions and efficacy in psychedelic clinical research in each setting. Manufacturing and patient access are separate issues. Related coverage: Czechia, which legalized medical psilocybin while practical access remained stalled. An industrial announcement does not guarantee each product’s quality, approval or effective access; those claims require their own documents and checks.
Source
- Calcalist (CTech). Israeli startup bets on psychedelic mushrooms for mental health treatment. CTech by Calcalist, May 3, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
